HIV Drugs Market Set to Reach $42.34 Billion by 2029 with 3.8% Yearly Growth

What industry-specific factors are fueling the growth of the hiv drugs market?
The HIV drug market's expansion is significantly propelled by the growing public knowledge concerning HIV disease detection and treatment. Due to its chronic nature, HIV/AIDS's high prevalence globally has stimulated unprecedented disease awareness. As an illustration, the United Nations International Children's Emergency Fund (UNICEF), a humanitarian aid organization based in the U.S., reported in July 2024 that an estimated 40.0 million people were living with HIV worldwide in 2023, of which 2.38 million were children between 0 and 19 years of age. Every day in 2023, about 685 children contracted HIV, and roughly 250 children died from AIDS. As such, the escalating public consciousness concerning the detection and treatment of HIV disease serves as a crucial stimulant for the HIV drug market's growth.

Get Your HIV Drugs Market Report Here:
https://www.thebusinessresearchcompany.com/report/hiv-drug-global-market-report

What Is the projected market size and growth rate for the hiv drugs market?
The market for HIV medications has been advancing progressively over the recent past. Its growth is expected to increase from $34.91 billion in 2024 to $36.41 billion in 2025, with a compound annual growth rate (CAGR) of 4.3%. Several factors have contributed to the historic period's growth including bolstered government backing and initiatives, a surge in healthcare spending, increased funding for HIV research and development, a rising number of HIV infections, elevated awareness, and economic expansion in burgeoning markets.

Anticipated to experience consistent expansion in the coming years, the market size of HIV drugs is projected to rise to $42.34 billion in 2029, with a compound annual growth rate (CAGR) of 3.8%. The upswing throughout the forecast period is due to factors such as boosted governmental assistance and initiatives, increased expenditure on healthcare, bolstered HIV research and development budgets, rising HIV infection rates, enhanced awareness, and economic progression in emerging markets. Key trends for the forecast period encompass investment in 3D bioprinting technology, the introduction of innovative new products, the development of multi-class combining products for HIV treatment, and the growth of strategic collaborations and partnerships.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2834&type=smp

What are the most significant trends transforming the hiv drugs market today?
In an effort to expedite drug development, expand treatment access, and bolster their international market reach, key players in the HIV drugs market are forging strategic alliances for the production of Lenacapavir. This first-in-class HIV-1 capsid inhibitor combines well with other antiretrovirals and targets various phases of the HIV lifecycle, representing a potentially effective treatment option for patients with few alternatives. For example, in August 2023, Dr. Reddy's Laboratories and Hetero, two pharmaceutical companies rooted in India, entered into a partnership with Gilead Sciences Inc., a biopharmaceutical firm based in the US. The goal of this collaboration is to produce and distribute the HIV drug lenacapavir across 120 primarily low- and lower-middle-income nations. They intend to widen the availability of this cutting-edge treatment, which is especially favourable for patients with multi-drug-resistant HIV and already extensive treatment histories.

What major market segments define the scope and growth of the hiv drugs market?
The HIV drugs market covered in this report is segmented -

1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT's), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types
2) By Administration: Oral, Parenteral
3) By Application: Hospital Pharmacies, Retail Pharmacies, Other Applications

Subsegments:
1) By Nucleoside Reverse Transcriptase Inhibitors (NRTIs): Zidovudine (AZT), Lamivudine (3TC), Abacavir (ABC), Tenofovir disoproxil fumarate (TDF), Other NRTIs
2) By Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Efavirenz (EFV), Nevirapine (NVP), Etravirine (ETR), Rilpivirine (RPV), Other NNRTIs
3) By Protease Inhibitors (PIs): Ritonavir (RTV), Lopinavir (LPV), Darunavir (DRV), Atazanavir (ATV), Other PIs
4) By Integrase Strand Transfer Inhibitors (INSTIs): Raltegravir (RAL), Dolutegravir (DTG), Bictegravir (BIC), Other INSTIs
5) By Other Types: Entry Inhibitors, Fusion Inhibitors, Combination Therapies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2834

Which region dominates the hiv drugs market?
North America was the largest region in the HIV drugs market share in 2024. Middle East is expected to be the largest growing region in the global HIV drug market during the forecast period. The regions covered in the HIV drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which key market leaders are driving the hiv drugs industry growth?
Major companies operating in the HIV drugs market include Gilead Sciences Inc., Johnson & Johnson, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Cipla, Aurobindo Pharma, AbbVie, Emcure Pharmaceuticals, Micro Labs Limited, Northeast Pharmaceutical Group Co. Ltd, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd, Strides Arcolab Limited, Hetero Labs Limited, Shanghai Desano Bio-pharmaceutical Co., Anhui Biochem Biopharmaceutical Co. Ltd., China's National Health Commission (NHC), Shanghai Xinxing Medicine Co. Ltd., China Meheco Xinxing Pharma Co. Ltd., CytoDyn Inc., Janssen Pharmaceutical, Bavarian Nordic, Roche Laboratories, Pharmstandard, Pharmasyntez, R-Pharm, Alium, ChemRar Group, Gritstone Oncology, Enzolytics Inc., BioClonetics Immunotherapeutics Inc., Dewpoint Therapeutics, Lyndra Therapeutics, Mylan N.V., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Teva Canada, ViiV Healthcare Canada, GSK, Abbott Laboratories, Aspen Pharmacare Limited, Pharmacare Ltd.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=2834&type=smp

What Is Covered In The HIV Drugs Global Market Report?

• Market Size Forecast: Examine the hiv drugs market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the hiv drugs market for a structured understanding.
• Key Players Overview: Analyze major players in the hiv drugs market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the hiv drugs market.
• Segment Contributions: Evaluate how different segments drive overall growth in the hiv drugs market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the hiv drugs market.
• Industry Challenges: Identify potential risks and obstacles affecting the hiv drugs market.
• Competitive Landscape: Review strategic developments in the hiv drugs market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.